My watch list  


Genmab A/S
Public (OMX: GEN)
HeadquartersCopenhagen, Denmark
Key peopleLisa Drakeman (President and CEO)
Michael Widmer (Chairman of the board)
ProductsPharmaceuticals, antibodies
RevenueDKK 135.5 million (2006)[1]
Profit DKK 438.2 million (2006)[1]
Employees237 (2006)[1]

Genmab A/S (OMX: GEN) is a Danish pharmaceutical company, founded in February 1999 and based in Copenhagen. Internationally, it operates through the subsidiaries Genmab BV in Utrecht, The Netherlands, Genmab Ltd in Hertfordshire, United Kingdom and Genmab, Inc in Princeton, New Jersey, USA, and is publicly traded on the OMX Nordic Exchange and the OMX Copenhagen 20.[2]

Research Pipeline

Status of major offerings in Genmab's research pipeline, as of late 2007.[3]

Name Indications Status Collaborations
Cutaneous T Cell lymphoma (CTCL) Phase III
Non-cutaneous T Cell lymphoma (NCTCL) Phase II (completed)
Chronic lymphocytic leukemia (CLL) Phase III GSK
Non-Hodgkin’s lymphoma (NHL) Phase III
Rheumatoid Arthritis (RA) Phase III
Diffuse large B cell lymphoma (DLBCL) Phase II
Head and neck cancer Phase III n/a
Non small cell lung cancer Phase II n/a
(AMG 714)
Rheumatoid Arthritis (RA) Phase II (completed) Amgen
Psoriasis Phase I
HuMax-IL8 Palmoplantar pustulosis Phase I/II (completed)
HuMax-CD38 Multiple myeloma Phase I/II
R1507 Cancer Phase I (completed) Roche
Roche 2 undisclosed Phase I Roche
Roche 3 undisclosed Phase I Roche
Roche 4 Asthma Phase I Roche
HuMax-HepC Hepatitis C pre-clinical Connex GmbH and INSERM
HuMax-TAC Organ transplant rejection Pre-clinical


  1. ^ a b c Annual Report 2006. Genmab A/S (29 March, 2007). Retrieved on 2007-12-19.
  2. ^ Company Profile from the Genmab website
  3. ^

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Genmab". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE